Preparation and characterization of chitosan-loaded antigen nanoparticles for immunization
|Doctorant :||Maruthi PRASANNA|
|Directeur de thèse :||Cyrille GRANDJEAN , Directeur de recherche CNRS|
|co-directeur de thèse :||Noemí Csaba, Associate Professor, University of Santiago de Compostela, Spain|
|Encadrant :||Cyrille GRANDJEAN , Directeur de recherche CNRS|
|Date de la soutenance :||vendredi 11 septembre 2020, 11h00|
This study is of great importance for the advancement in the development of pneumococcal vaccines and the improvement of their efficacy. Indeed, researchers have succeeded in preparing and characterizing chitosan nanoparticles loaded with antigen, suitable for immunization.
The currently available pneumococcal vaccines are not effective in complete prevention of pneumococcal infections. To develop a better vaccine, first, “we were able to produce a glycoconjugate antigen (molecule resulting from the binding of carbohydrates to proteins or carbohydrates to lipids) based on a common pneumococcal vaccine. On the basis of the positive immune responses generated by the glycoconjugate antigen in mice, we further envisaged that their combination with the nanotechnologies would generate a vaccine with enhanced potential,” explains Maruthi Prasanna.
Following this approach, chitosan nanoparticles were used to encapsulate the glycoconjugate. Finally, the developed nanovaccines generated an enhanced immune response against both the protein and polysaccharide components when compared to the naked glycoconjugate.
Frontiers in Chemistry, 7 (November), p. 1–9, 2019, ISSN: 22962646.
European Journal of Pharmaceutical Sciences, 129 , p. 31–41, 2019, ISSN: 0928-0987.